Turnstone Biologics (NASDAQ:TSBX) just reported results for the fourth quarter of 2023.
- Turnstone Biologics reported earnings per share of -73 cents. This was above the analyst estimate for EPS of -86 cents.
- The company did not report any revenue for the quarter.